Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Burger, Jan A., Sivina, Mariela, Jain, Nitin, Kim, Ekaterina, Kadia, Tapan, Estrov, Zeev, Nogueras-Gonzalez, Graciela M., Huang, Xuelin, Jorgensen, Jeffrey, Li, Jianling, Cheng, Mei, Clow, Fong, Ohanian, Maro, Andreeff, Michael, Mathew, Thomas, Thompson, Philip, Kantarjian, Hagop, O’Brien, Susan, Wierda, William G., Ferrajoli, Alessandra, Keating, Michael J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2019
Предметы:
Plenary Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6405333/
https://ncbi.nlm.nih.gov/pubmed/30530801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-10-879429
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы